Benzyl Alcohol (CID 244) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(9)
 
 
Inactive(220)
 
 
Inconclusive(45)
 
 
Unspecified(152)
 
 
Top Targets:
7TM GPCR Srx(12)
 
 
7TM GPCR Srsx(10)
 
 
p450(10)
 
 
 
NR LBD PPAR(5)
 
 
NR LBD ER(4)
 
 
 
BioAssay Types:
Confirmatory(184)
 
 
 
 
 
Literature(80)
 
 
 
 
 
Screening(4)
 
 
BioActivity Types:
Potency(148)
 
 
 
 
 
IC50(116)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 353    Data Row: 426   Total Pages: 9   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID17390015]
Potency 5.3582Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation [AID504832, Type: confirmatory]
View
2
[SID17390015]
Potency 6.012Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation [AID504834, Type: confirmatory]
View
3
[SID48415620]
 DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
4
[SID17390015]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_19, Type: Literature]
View
5
[SID17390015]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_3, Type: Literature]
View
6
[SID17390015]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_43, Type: Literature]
View
7
[SID17390015]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_44, Type: Literature]
View
8
[SID17390015]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_51, Type: Literature]
View
9
[SID17390015]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_57, Type: Literature]
View
10
[SID103196411]
Km 50Apparent Michaelis constant (Km) against Arylsulfotransferase (AST IV) [AID39219, Type: Literature]
View
11
[SID103196411]
 Maximal velocity (Vmax) against Arylsulfotransferase (AST IV) [AID39220, Type: Literature]
View
12
[SID103196411]
 Inhibition of Rana pipiens muscle activity. [AID168703, Type: Literature]
View
13
[SID103196411]
 Ratio of kcat/Km determined for catalytic efficiency in sulfonation against AST IV [AID229377, Type: Literature]
View
14
[SID103196411]
 Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system [AID237685, Type: Literature]
View
15
[SID103196411]
 Permeability coefficient in human skin [AID311367, Type: Literature]
View
16
[SID103196411]
 Binding affinity to beta cyclodextrin [AID346025, Type: Literature]
View
17
[SID103196411]
 Partition coefficient (logP) [AID24226, Type: Literature]
View
18
[SID103196411]
 Partition coefficient (logP) (dodecane) [AID28956, Type: Literature]
View
19
[SID103196411]
 Partition coefficient (logP) [AID28957, Type: Literature]
View
20
[SID17390015]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749, Type: Literature]
View
21
[SID103196411]
 Effect on growth in Staphylococcus aureus MN8 at 0.50 % after 24 hrs (Rvb = 100%) [AID555340, Type: Literature]
View
22
[SID103196411]
 Effect on growth in Staphylococcus aureus MN8 at 0.10 % after 24 hrs (Rvb = 100%) [AID555341, Type: Literature]
View
23
[SID103196411]
 Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 0.50 % after 24 hrs relative to control [AID555372, Type: Literature]
View
24
[SID103196411]
 Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 0.10 % after 24 hrs relative to control [AID555373, Type: Literature]
View
25
[SID103196411]
 Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset [AID588220, Type: Literature]
View
26
[SID103196411]
 Specific activity of expressed human recombinant UGT1A9 [AID624612, Type: Literature]
View
27
[SID103196411]
IC50 DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) [AID625158, Type: other]
View
28
[SID103196411]
 DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu) [AID625164, Type: other]
View
29
[SID103196411]
IC50 DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP) [AID625165, Type: other]
View
30
[SID103196411]
IC50 DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP) [AID625166, Type: other]
View
31
[SID103196411]
 DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) [AID625169, Type: other]
View
32
[SID103196411]
IC50 DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) [AID625170, Type: other]
View
33
[SID103196411]
 DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) [AID625189, Type: other]
View
34
[SID103196411]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) [AID625190, Type: other]
View
35
[SID103196411]
IC50 DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine) [AID625197, Type: other]
View
36
[SID103196411]
IC50 DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP) [AID625210, Type: other]
View
37
[SID103196411]
 DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)) [AID625211, Type: other]
View
38
[SID103196411]
IC50 DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin) [AID625212, Type: other]
View
39
[SID103196411]
IC50 DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem) [AID625215, Type: other]
View
40
[SID103196411]
IC50 DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine) [AID625216, Type: other]
View
41
[SID103196411]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630) [AID625219, Type: other]
View
42
[SID103196411]
IC50 DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil) [AID625224, Type: other]
View
43
[SID103196411]
IC50 DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin) [AID625225, Type: other]
View
44
[SID103196411]
 DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha) [AID625230, Type: other]
View
45
[SID103196411]
IC50 DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888)) [AID625234, Type: other]
View
46
[SID103196411]
IC50 DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol) [AID625260, Type: other]
View
47
[SID103196411]
IC50 DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam) [AID625261, Type: other]
View
48
[SID103196411]
IC50 DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB) [AID625262, Type: other]
View
49
[SID103196411]
IC50 DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA) [AID625264, Type: other]
View
50
[SID103196411]
 DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid) [AID625265, Type: other]
View